ResearcherSheng Jing HospitalActive in the last 2 years

Yuhe Lin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6125-1001, 0000-0003-1317-6294; OpenAlex author ID A5025597687. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2024: 2 papers

Papers 2

LPCAT2-mediated lipid droplet production supports pancreatic cancer chemoresistance and cell motility. Co-author DOI 10.1016/j.intimp.2024.112681 ↗
B3GNT5 is a novel marker correlated with malignant phenotype and poor outcome in pancreatic cancer. Last author DOI 10.1016/j.isci.2024.110889 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Wei Yao · 1 shared paper, 2024 · strength 0.31
- Paper B3GNT5 is a novel marker correlated with malignant phenotype and poor outcome in pancreatic cancer. DOI 10.1016/j.isci.2024.110889 ↗
Xin Zhang · 1 shared paper, 2024 · strength 0.31
- Paper B3GNT5 is a novel marker correlated with malignant phenotype and poor outcome in pancreatic cancer. DOI 10.1016/j.isci.2024.110889 ↗
Yao Wei · 1 shared paper, 2024 · strength 0.31
- Paper LPCAT2-mediated lipid droplet production supports pancreatic cancer chemoresistance and cell motility. DOI 10.1016/j.intimp.2024.112681 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.